Lumentin 44 - Lument AB
Alternative Names: Lumentin; Lumentin-44Latest Information Update: 28 Mar 2023
At a glance
- Originator Lument AB
- Class Albumins; Contrast media; Diagnostic agents; Imaging agents
- Mechanism of Action Emission-computed tomography enhancers; Magnetic resonance imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Inflammatory bowel diseases
Most Recent Events
- 28 Feb 2023 Lument AB completes a phase II trial in Inflammatory bowel diseases (Diagnosis, In volunteers) in Sweden (NCT05781490)
- 06 Feb 2023 Phase-II clinical trials in Inflammatory bowel diseases (Diagnosis, In volunteers) in Sweden (PO) (NCT05781490)
- 27 Jul 2022 Lumentin 44 is still in phase II trials for Inflammatory bowel diseases (Diagnosis, In adults, In the elderly) in Sweden (PO)